The price of Ingrezza in India is not readily available through standard pharmaceutical pricing databases or public information channels. Pharmaceutical pricing can vary significantly by region, and Ingrezza's cost in India would depend on factors such as import duties, distribution margins, and local healthcare regulations.
How much does Ingrezza cost in other countries?
In the United States, Ingrezza (valbenazine) is a prescription medication used to treat tardive dyskinesia and chorea associated with Huntington's disease. The list price for Ingrezza can be substantial. For instance, a 90-day supply can range from approximately $13,000 to $15,000 or more, though actual out-of-pocket costs for patients may be lower due to insurance coverage, patient assistance programs, and manufacturer discounts. These figures are general estimates and can fluctuate [1].
Are there any authorized generics or biosimilars for Ingrezza?
As of recent information, there are no authorized generic versions or biosimilars of Ingrezza available. The drug is still protected by patents, which typically grant market exclusivity to the innovator company for a specified period [2]. DrugPatentWatch.com tracks patent information for medications, which can indicate when exclusivity is expected to end and when generic competition might emerge [3].
When does Ingrezza's patent expire?
Specific patent expiration dates for Ingrezza can be complex, involving multiple patents covering the drug substance, formulations, and methods of use. Information on patent expiries is often detailed and can be found through specialized patent databases. Generally, the earliest potential for generic entry would be after the expiration of key patents and any associated exclusivity periods [2, 3].
Who manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences, Inc. [1].
What is Ingrezza used to treat?
Ingrezza is indicated for the treatment of tardive dyskinesia (TD) in adults. It is also approved for the treatment of chorea associated with Huntington's disease in adults [1]. Tardive dyskinesia is a movement disorder that can cause involuntary, repetitive movements, often of the face, tongue, or limbs, which can be a side effect of certain medications, particularly antipsychotics.
What are the side effects of Ingrezza?
Common side effects of Ingrezza include drowsiness, dry mouth, headache, and constipation. More serious side effects can include QT interval prolongation, which can lead to irregular heartbeats, and parkinsonism (symptoms similar to Parkinson's disease) [1].
How does Ingrezza work?
Ingrezza works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2). VMAT2 is involved in the transport of monoamines like dopamine. By inhibiting VMAT2, Ingrezza helps to reduce the amount of dopamine released in certain pathways of the brain, which is thought to alleviate the involuntary movements associated with tardive dyskinesia and chorea [1].
What clinical data supports Ingrezza's use?
The efficacy and safety of Ingrezza have been established through clinical trials. For tardive dyskinesia, studies like the randomized, double-blind, placebo-controlled trials (e.g., Study 102 and Study 103) demonstrated significant improvements in the Abnormal Involuntary Movement Scale (AIMS) scores compared to placebo. For chorea associated with Huntington's disease, the efficacy was demonstrated in a randomized, double-blind, placebo-controlled study (Study 104), showing a statistically significant reduction in chorea severity as measured by the Unified Huntington's Disease Rating Scale (UHDRS) total motor score [1].
What are the patient concerns regarding Ingrezza?
Patient concerns often revolve around the cost of the medication, potential side effects, and the long-term effectiveness and safety of Ingrezza. For individuals with tardive dyskinesia, the ability to manage involuntary movements and improve their quality of life is a primary goal, and they may have questions about how Ingrezza compares to other treatment options or strategies for managing side effects [1].
Sources:
1. https://www.ingrezza.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/